These approvals will change the paradigm for treating cancer patients,” Narasimhan says. The medicine now approved for use ...

Vas Narasimhan said on Tuesday that if the U.S. adopts international drug pricing, all companies would have to “relook at ...

Novartis’ head of drug development Vas Narasimhan talks about the company’s stake in CAR-T immunotherapy. These cell therapies are set to transform treatment of blood cancers – but questions ...

Novartis is proud to share that CEO Vas Narasimhan, M.D., has been named to the 2025 TIME100 Health list—recognizing 100 of the most influential people driving the future of global health.

Vas Narasimhan, the CEO of Novartis, discusses the Swiss pharmaceutical company's first-quarter earnings. Coca-Cola on ...

CEO Vas Narasimhan said the company has more than 25 potential blockbusters in its pipeline. Psoriasis drug Cosentyx and heart failure drug Entresto are leading the charge among the company’s ...

Novartis’ new CEO Vas Narasimhan has said he wants to cut R&D costs by using digital tech, and has followed through by scaling up a virtual clinical trials collaboration with startup firm ...

"Even in this I think complex geopolitical environment, we feel confident we can deliver now this upgraded guidance," CEO Vas Narasimhan told CNBC's "Squawk Box Europe" on Tuesday. Sales continued ...

Novartis CEO Vas Narasimhan and Sanofi leader Paul Hudson wrote in Britain's Financial Times that European price controls and austerity measures reduce the attractiveness of its markets.